ThinPrep Imaging System with Dual Review; PAP Screening
American Bio-Clinical Laboratories is pleased to inform you that we recently implemented the ThinPrep Imaging System with Dual Review screening in our lab. This will further improve the performance of the ThinPrep Pap Test, your cervical cancer screening test of choice. The combination of the ThinPrep and the ThinPrep Imaging System adds up to the most comprehensive and accurate screening method available today.
The ThinPrep Imaging System with dual Review enhances the ThinPrep Pap Test by combining advanced screening technology with human interpretive expertise.
- Every patient is analyzed by the Imager and careened by a cytotechnologist
- This Dual Review screening approach has been shown to increase sensitivity over manual screening further reducing the rate of false negative fraction (ASC-US).
- Biopsy-confirmed peer-review study data shows improved disease detection with the ThinPrep Imaging System with Dual Review over manually screened ThinPrep slides.
The new test codes are 3387 for PAP only and 3398 for PAP w/Rfx to HPV. If the old test codes are ordered on non-revised requisitions, the new test codes will be ordered.
It is our goal to continue offering you the latest technology, so that you can provide the most accurate results for you patients. If you have any questions regarding this system, please call Frida Safavi or Dr. Richard Xing at (323)-222-6688.
Clostridium Difficile Toxic Gene Test Update
Effective Monday, September 29, 2014, American Bio-Clinical Laboratory will only perform the molecular DNA Amplification method for Clostridium difficile testing which will replace our current toxin assay. This assay utilizes molecular DNA Amplification to detect toxin gene sequences associated with toxin producing C. difficile. The assay provides a sensitivity of 98.2% and a specificity of 92.8% when compared to the gold standard of toxigenic culture. This new test methodology provides superior diagnostic accuracy, which eliminates the need for additional or repeat testing of patient samples. This change was made to be in alignment with the latest ASM guidelines for C. difficile testing and to deliver the highest quality patient results. Please note the following specimen and testing requirements.
- Limit testing to patients with ≥3 non-formed stool specimens per 24 period. Only liquid or soft stools (takes shape of container) are acceptable unless ileus (obstruction) is present. Formed stool will be rejected. Patients may be colonized with toxin-producing C. difficile strains that are not causing illness. Therefore, formed stools are not recommended for testing.
- Rejection of samples for test of cure. Repeat testing following a positive test (test of cure) is not recommended since patients may carry toxigenic C. difficile for months after clinical cure. Repeat testing following a positive test is appropriate if the patient improves with therapy and relapses after the completion of a treatment regimen (clinical relapse).
- Testing will be restricted to 1 specimen per 7 days. Molecular tests for C. difficile are highly sensitive and a negative result does not need to be confirmed by a second specimen.
Test ordering information:
|Test Name||Test Number||CPT||Sample|
|CDIFD||653||87493||Liquid or Soft, Unformed Stool|
Interpretive Information: Results will be reported as positive or negative for toxigenic C. difficile. Positive test:
- In adults, metronidazole is the treatment of choice except in cases of severe infection or therapeutic failure.
- C. difficile molecular tests are highly sensitive. Empiric therapy for patients with diarrhea and negative C. difficile test should be avoided.